The conjugation of the ubiquitin-like protein SUMO to lysine side chains plays widespread roles in the regulation of nuclear protein function. Since little information is available about the roles of SUMO in development, we have screened a collection of chromosomal deficiencies to identify developmental processes regulated by SUMO. We found that flies heterozygous for a deficiency uncovering vestigial (vg) and mutations in any of several genes encoding components of the SUMO conjugation machinery exhibit severe wing notching. This phenotype is due to an interaction between sumo and vg since it is suppressed by expression of Vg from a transgene, and is also observed in flies doubly heterozygous for vg hypomorphic alleles and sumo. In addition, the ability of Vg to direct the formation of ectopic wings when misexpressed in the eye field is enhanced by simultaneous misexpression of SUMO. In S2 cell transient transfection assays, overexpression of SUMO and the SUMO conjugating enzyme Ubc9, but not a catalytically inactive form of Ubc9, results in sumoylation of Vg and augments the activation of a Vg-responsive reporter. These findings are consistent with the idea that sumoylation stimulates Vg function during wing morphogenesis. q
Introduction
SUMO is one of multiple ubiquitin family proteins that become covalently attached to other proteins via an amide linkage between the C-terminal carboxyl group of the ubiquitin family protein and lysine side chains in the target proteins (Hay, 2005; Johnson, 2004; Melchior et al., 2003; Seeler and Dejean, 2003; Verger et al., 2003) . Conjugation of ubiquitin, the best characterized member of the family, to other proteins usually marks these proteins for destruction by the 26S proteasome; the ubiquitin/proteasome pathway is the major pathway for regulated protein degradation in eukaryotic cells (Hershko and Ciechanover, 1998) . In contrast, conjugation of SUMO to proteins does not mark them for destruction, but modifies their properties in other ways. For example, SUMO conjugation can direct proteins to specific subcellular locales including the nuclear PML oncogenic domains (PODs) (Ishov et al., 1999; Muller et al., 1998) ; stabilize proteins by antagonizing ubiquitylation (Desterro et al., 1998; Lin et al., 2003) ; or modulate transcription factor activity (Freiman and Tjian, 2003) .
Conjugation of SUMO to target proteins occurs via a three-step pathway that is very similar to the ubiquitin conjugation pathway. Steps 1 and 2 involve the successive covalent attachment of SUMO to catalytic cysteine residues in the heterodimeric SUMO activating enzyme SAE1/SAE2 and the SUMO conjugating enzyme Ubc9 . These two enzymes are homologous to the ubiquitin activating and conjugating enzymes.
Step 3, in which SUMO is transferred from Ubc9 to the lysine side chain of the conjugation target, can be stimulated by a SUMO ligase. In ubiquitin conjugation, similar ligases are usually essential for target selection. However, in the case of SUMO conjugation, specific contacts between Ubc9 and the substrate make important contributions to substrate selection, and thus the ligases may be relatively less important (Hochstrasser, 2002) . Nonetheless, recent studies provide evidence for multiple families of SUMO ligases , including the PIAS family proteins, which are found in yeast, Drosophila, and vertebrates (Hari et al., 2001; Johnson and Gupta, 2001; Kahyo et al., 2001; Takahashi et al., 2001) . Drosophila contains a single PIAS family member (alternatively referred to as Su(var)2-10, Zimp, and dPIAS), which has the ability to stimulate SUMO conjugation in vitro (our unpublished observations).
A large number of proteins, such as the nuclear pore protein RanGAP1, the POD component PML, and a wide variety of transcription factors including Dorsal, Tramtrack, c-Jun, and p53, are known to be substrates for sumoylation (Bhaskar et al., 2000; Lehembre et al., 2000; Muller et al., 2000; Seeler and Dejean, 2003) . In many but not all of these substrates, the sumoylated lysine residue resides in a jKxE motif (in which j represents an amino acid with a hydrophobic side chain) (Johnson and Blobel, 1999; Rodriguez et al., 2001) .
While many SUMO conjugation targets have been identified, genetic analysis to demonstrate the physiological relevance of SUMO conjugation to specific proteins is generally lacking. In an effort to identify relevant sumoylation targets, we have carried out a genetic screen in Drosophila looking for genes that interact with genes encoding components of the sumoylation machinery. The screen revealed a possible role for SUMO in the function of Vestigial (Vg), a protein normally expressed in the wing field of the wing imaginal disc (Williams et al., 1991) .
The vg gene is a selector gene for wing development; loss of function vg mutations result in under proliferation of the wing disc leading to notched or severely truncated wings, while ectopic expression of Vg in other imaginal discs induces outgrowth and wing tissue specification (BaenaLopez and Garcia-Bellido, 2003; Kim et al., 1996; Paumard-Rigal et al., 1998) . Vg, which is not itself a DNA binding protein, interacts with the DNA binding TEA family transcription factor Scalloped (Sd), forming an activation complex (Campbell et al., 1992; Halder and Carroll, 2001; Halder et al., 1998; Simmonds et al., 1998) . During larval development, Vg expression in the wing disc depends on two intronic enhancers: the boundary enhancer (VgBE), which mediates regulation by the Notch pathway (Kim et al., 1996; Williams et al., 1994) , and the quadrant enhancer (VgQ), which mediates regulation by the Dpp pathway (Kim et al., 1997 (Kim et al., , 1996 . Both of these enhancers also contain autoregulatory elements that interact with the Vg/Sd complex (Halder et al., 1998) .
We have found a dosage sensitive genetic interaction between vg and components of the SUMO conjugation machinery including SUMO itself, Ubc9, and dPIAS. Furthermore, we have found that Vg is a substrate for sumoylation and that transcriptional activation by Vg in S2 cells is potentiated by the SUMO conjugation machinery. Thus, our findings suggest a novel role for sumoylation in wing development.
Results

Mutations in SUMO pathway components enhance a wing defect due to a second chromosome deficiency
To look for novel targets or regulators of the SUMO conjugation pathway, we screened a deficiency kit covering much of the Drosophila euchromatic genome for deficiencies that resulted in visible phenotypes when combined with mutations in components of the SUMO conjugation pathway. One second chromosome deficiency (Df(2R)CX1) was found with the desired properties. Flies heterozygous for Df(2R)CX1 alone exhibited mild wing notching in up to 60% of the individuals, while flies heterozygous for mutant alleles of genes encoding SUMO conjugation pathway components exhibited wild-type wings in 100% of the individuals. However, the wing phenotype was much more severe when we combined Df(2R)CX1 with mutant alleles of sumo, ubc9, or dpias (Fig. 1E ). Wing phenotypes were divided into four categories ranging from wild-type ( Fig. 1A) , to mildly notched (Fig. 1B) , to severely notched ( Fig. 1C) , to severely notched and diminished in size (Fig. 1D ). In flies that were doubly heterozygous for Df(2R)CX1 and mutant alleles of sumo or ubc9, 100% of the wings were defective with greater than 80% being severely notched or severely notched and diminished in size. In flies that were doubly heterozygous for Df(2R)CX1 and a mutant allele of dpias, greater than 80% of the wings were defective and the defects were, on average, significantly more severe than those observed in the absence of the dpias mutation.
Genetic interactions between vg and sumo
vg, a gene with known roles in wing patterning, lies in the region uncovered by Df(2R)CX1 (Nagaraj et al., 1999) . We therefore determined if vg expression could rescue the notched wing phenotype observed in Df(2R)CX1, sumo heterozygotes. To drive Vg expression in the correct domain, we employed a vg-Gal4 driver in combination with UAS-vg. Expression of Vg by this approach largely rescued the notched wing phenotype observed in Df(2R)CX1, sumo heterozygotes strongly suggesting that vg is a sumo-interacting gene ( Fig. 2A-D) .
To verify the interaction, we employed two hypomorphic vg alleles, vg 1 and vg np . Flies heterozygous for either vg allele have wild-type wing morphology ( Fig. 2E and I ), while vg 1 homozygotes exhibit severely diminished wings ( Fig. 2G ) and vg np homozygotes exhibit notched wings (Fig. 2K ). Flies doubly heterozygous for either vg allele and the sumo mutant allele exhibit variable degrees of wing notching (Fig. 2F, J ). In the case of the vg np , sumo/C flies, the wing notching is as severe as that observed for vg np homozyotes (compare Fig. 2J and K). One dose of the mutant sumo allele also enhances the homozygous vg np notched wing phenotype (compare Fig. 2K and L) , and may exacerbate the homozygous vg 1 phenotype (compare Fig. 2G and H) .
Further evidence that Vg and SUMO work together is provided by experiments in which the two genes were simultaneously overexpressed in the wing or eye. Overexpression of SUMO using the vg driver results in no phenotype (Fig. 3A) . Overexpression of Vg using the vg driver results in wings that are somewhat smaller than normal, but that have otherwise normal morphology including normal venation (Fig. 3B) . However, simultaneous overexpression of Vg and SUMO in the wing results in extra veins including extra crossveins and short additional longitudinal veins (Fig. 3C,D) . Previous studies have shown that overexpression of Vg using the dpp-Gal4 driver results in ectopic wings in the eye (Kim et al., 1996) . To obtain further evidence for a role of sumoylation in Vg function, we looked at the effect of SUMO overexpression on ectopic wing formation in the eye. Rather then using the dpp driver, we employed the eyeless (ey) driver to restrict expression to the eye/antennal disc. We found that expression of Vg using the ey-Gal4 driver results in variable phenotypes, including rough eyes (Fig. 3E, 18% ), loss of eyes (Fig. 3F, 2% ), small ectopic wings in the eye field (Fig. 3G, 67%) , and large ectopic wings in the eye field (Fig. 3H, 13% ). While overexpression of SUMO by itself results in no eye phenotype, the simultaneous overexpression of Vg and SUMO in the eye enhances the Vg overexpression phenotype such that 98% of the resulting flies exhibit ectopic wings in the eye field (44% exhibit small ectopic wings, while 54% exhibit large ectopic wings, Fig. 3I ).
The dosage sensitive interaction that we observe between sumo and vg is highly specific. For example, we tested for interactions between sumo and a number of genes known to interact with vg, including Scalloped, wingless, Notch, groucho, and vein, and none of these genes were found to interact with sumo (data not shown).
SUMO pathway components potentiate activation by Vg in S2 cells
To test the possibility that Vg might be a direct target for sumoylation, we coexpressed Vg with SUMO and Ubc9 in S2 cells (Fig. 4A) . The recombinant Vg expressed in this experiment was tagged with both the V5 epitope and a 6xHis tag. Recombinant Vg was then immunoprecipitated with the anti-V5 antibody, and the immunoprecipates were resolved by SDS-PAGE and subjected to immunoblotting with antibodies against the His tag (left panel) and with antibodies against SUMO (right panel). In the absence of coexpressed SUMO and Ubc9 (lane 1), the blots reveal a protein band with an apparent molecular mass of 52 kDa representing unmodified Vg and a 72 kDa band. The 72 kDa band, which is not abundant enough to be detected in the anti-his blot, but is readily apparent in the anti-SUMO blot, likely represents SUMO-modified Vg as the addition of a single SUMO adduct increases the apparent molecular mass of SUMO conjugation targets by 20 kDa (Bhaskar et al., 2002, Vg is a transcription factor that works together with Sd to activate various targets in the imaginal discs. For example, Vg activates its own expression via a regulatory module termed the VgQ enhancer. The Vg dependent activity of the VgQ enhancer can be demonstrated using reporter assays in transiently transfected S2 cells (Halder et al., 1998) . The combination of Vg and Sd results in about a two to threefold increase in the activity of a luciferase reporter containing the VgQ enhancer (Fig. 4B ). This activation is increased up to another two-fold by the cotransfection of vectors encoding SUMO and Ubc9. Evidence that sumoylation is required for activation of Vg by the sumoylation machinery is provided by an experiment in which we replaced wild-type recombinant Ubc9 with a mutant form of Ubc9 containing a single amino acid change in the catalytic site that abolishes SUMO conjugation activity. This mutation also abolishes the stimulatory effect of Ubc9 on activation by Vg (Fig. 4C ).
Discussion
Sumoylation potentiates Vg function
The results presented here show that sumo loss-offunction mutations act as genetic enhancers of vg loss-offunction mutations. For example, flies doubly heterozygous for recessive hypomorphic vg alleles and recessive sumo or ubc9 alleles exhibit wing notching that is as severe as that exhibited by flies homozygous for the vg mutant alleles. In addition, co-overexpression of SUMO and Vg in the wing or eye significantly exacerbates the phenotype due to overexpression of Vg alone. These findings are consistent with the idea that the SUMO machinery acts to augment Vg function. However, our attempts to further confirm this idea by generating homozygous SUMO loss-of-function clones in discs have failed, probably because SUMO is required for cell cycle progression or cell survival.
Our transient transfection assays further support the idea that the sumoylation machinery can potentiate Vg/Sd transactivation. Specifically, we observe that cotransfection of Ubc9 and SUMO augments the Vg/Sd dependent activation of the VgQ-luciferase reporter. This effect requires a catalytically active form of Ubc9 strongly suggesting that it is dependent upon sumoylation.
We have attempted to map the SUMO acceptor lysine in Vg. There is only a single lysine (Lys 180) that falls in a sequence context with any resemblance to the consensus sumoylation site. Lys 180 falls in the sequence TKEE, while the sumoylation consensus is jKxE (with j signifying a hydrophobic residue). Surprisingly, however, mutagenesis of this lysine to arginine does not significantly reduce the ability of Vg to serve as a target for sumoylation in S2 cells (data not shown). Apparently, sumoylation occurs at nonconsensus sites in Vg. There are multiple precedents for such non-consensus sites in other sumoylation targets (Johnson and Blobel, 1999; Rodriguez et al., 2001) .
The mechanism by which sumoylation renders Vg a more potent activator appears to be distinct from the mechanism by which sumoylation regulates a number of transcription factors. There are numerous examples in which sumoylation of a transcription factor alters the subcellular localization of a factor by directing it to the PODs, resulting in either the activation or inhibition of the factor (Ishov et al., 1999; Muller et al., 1998) . However, immunofluorescence studies reveal no evidence for an effect of sumoylation on Vg subcellular localization (data not shown). There are also numerous examples in which sumoylation upregulates a transcription factor by disrupting an interaction with a negative regulatory factor (Abdel-Hafiz et al., 2002; Bhaskar et al., 2002; Bies et al., 2002; Kim et al., 2002; Le Drean et al., 2002) . Although we cannot rule out the existence of a similar negatively acting factor in the case of Vg, there is no direct evidence for such a factor. An alternative intriguing possibility, which remains to be explored, is that the sumoylation of Vg enhances transcription by enhancing the interaction between Vg and Sd.
Genetic analysis reveals multiple roles for sumoylation in metazoan biology
This study represents one of only a few efforts using genetic approaches to illuminate the biological role of SUMO conjugation in a multicellular organism. Previous genetic analyses have demonstrated a role for the sumoylation machinery in embryonic patterning. For example, in C. elegans embryos, loss of SUMO, Ubc9, or the SUMO activating enzyme results in homeotic transformations apparently due to a role for sumoylation in the function of the Polycomb group protein SOP-2 (Zhang et al., 2004) . In Drosophila embryos, loss of Ubc9 results in the deletion of variable numbers of thoracic and anterior abdominal segments, but in this case the relevant sumoylation target is not known (Epps and Tanda, 1998) . Previous genetic analysis also suggests a role for sumoylation in immune system function as mutations in sumo or ubc9 compromise the Drosophila innate immune response by attenuating the LPS-induced expression of genes encoding anti-microbial peptides such as Cecropin A1 (Bhaskar et al., 2002) . This is consistent with the finding that sumoylation significantly stimulates the function of the Drosophila rel family protein Dorsal since rel family proteins play critical roles in both vertebrate and invertebrate innate immunity. Finally, a recent yeast two-hybrid screen indicates that Dof, a cytoplasmic components of the FGF signaling pathway, interacts with multiple components of the SUMO conjugation pathway. This suggests possible roles for SUMO conjugation in the morphogenetic processes controlled by FGF receptors such as mesodermal and tracheal morphogenesis (Battersby et al., 2003) . Thus, our finding of a likely role for sumoylation in wing development adds to a growing body of evidence suggesting pleiotropic roles for sumoylation in the development and function of multicellular organisms.
Experimental procedures
Fly stocks and germ line transformation
The deficiency screen employed the Bloomington Stock Center deficiency kit. We utilized the following fly lines: sumo 04493 (smt3 04493 ), lwr 05486 (Ubc9 05486 ), Su(var)2-10 03687 (dPIAS 03687 ) (Spradling et al., 1999) , vg 1 and vg np (Lindsley and Zimm, 1992) vg-Gal4 (Simmonds et al., 1995) , ey-Gal4 (Hazelett et al., 1998) , and UAS-vg (Kim et al., 1996) . To create the UAS-sumo lines, a UAS-sumo vector was created by PCR amplification of the sumo cDNA with primers containing EcoRI and Bgl II sites and insertion of the product into pUAST. P element mediated germ line transformation was performed by standard methods (Roberts, 1998) . The stocks were homozygous viable.
Transient transfection of Drosophila S2 cells
A pAc5-Vg vector was created by PCR amplification of the vg cDNA with primers containing EcoRI and Xho I sites and insertion of the amplification product into an EcoRI/Xho I-digested pAc5 vector (Invitrogen). A pAc5-Sd vector was created by PCR amplification of the sd cDNA with primers containing Kpn I sites and insertion of the amplification product into a Kpn I-digested pAc5 vector. The VgQ reporter vector was generated by annealing double-stranded oligonucleotides (5 0 CGG GGT ACC ttg gct gcc gtc gcg att cga caa ctt tgg ccg gca cgt tgg cg 3 0 , and 5 0 ctt tgg ccg gca cgt tgg cga gtg tgc cat gca tgc tga tga cg TCT AGA GC 3 0 (Certel et al., 2000) ), and inserting them into a Kpn I/Xba I-digested pGL3-promoter vector (Promega). The pPAC-FLAG-SUMO, pPAC-HA-Ubc9, and pPAC-HA-Ubc9 mutant vectors have been previously described (Bhaskar et al., 2002 (Bhaskar et al., ., 2000 Smith et al., 2004) Calcium phosphate cotransfections into Drosophila S2 cells were carried out as described previously (Echalier, 1997) . For reporter assays, each transfection consisted of 2 mg of pGL3-VgQ, 1 mg of pAc5-Vg, 1 mg of pAc5-Sd, 0.067 mg of pRL-TK (internal control, Promega), and the indicated amounts of pPAC-FLAG-SUMO, pPAC-HAUbc9, or the pPAC-HA-Ubc9 mutant. The luciferase reporter activities were determined with the Dual-luciferase assay system (Promega).
Immunoprecipitation and western blot analysis
For immunoprecipitation experiments, cells were harvested and dissolved in RIPA buffer (50 mM Tris-HCl [pH8.0], 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 1% SDS, 1 mM DTT and protease inhibitor [complete, EDTA-free, Roche]). Equivalent amounts of total protein were precleared with protein A beads (Sigma), and immunoprecipitaed with 2 mg of anti-V5 mouse antibody (Invitrogen). Western blots were carried out as described previously (Smith et al., 2004) . Blots were conducted by the ECL method with the following antibodies (rabbit anti-SUMO antiserum, 1:1000, or mouse anti-his tag antibody (Affinity Bioreagents), 1:1000).
